T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BFS
726
Saul Centers
BFS
$858M
| $112M | 0.01% |
2,115,653
-26,733
| -1% | -$1.33M |
|
|
EFOR
727
Everforth Inc
EFOR
$1.37B
| $112M | 0.01% |
907,244
-20,464
| -2% | -$2.5M |
|
728
NovoCure
NVCR
$2.05B
| $112M | 0.01% |
1,486,168
+53,701
| +4% | +$5.39M |
|
729
Alignment Healthcare
ALHC
$2.82B
| $111M | 0.01% |
7,914,926
-549,331
| -6% | -$9.62M |
|
730
Agilon Health
AGL
$1.53B
| $111M | 0.01% |
164,389
-20,616
| -11% | -$12.5M |
|
731
Flywire
FLYW
$2.23B
| $111M | 0.01% |
2,903,610
+1,388,744
| +92% | +$59.4M |
|
|
STL
732
DELISTED
Sterling Bancorp
STL
| $109M | 0.01% |
4,244,477
+4,146,012
| +4,211% | +$107M |
|
733
Palo Alto Networks
PANW
$322B
| $109M | 0.01% |
1,177,074
-63,528
| -5% | -$5.5M |
|
734
McGrath RentCorp
MGRC
$2.92B
| $109M | 0.01% |
1,356,176
-57,630
| -4% | -$4.45M |
|
|
AVTR.PRA
735
DELISTED
Avantor, Inc. Series A Mandatory Convertible Preferred Stock
AVTR.PRA
| $108M | 0.01% |
+837,145
| New | +$101M |
|
736
ResMed
RMD
$32.9B
| $108M | 0.01% |
415,841
+49,250
| +13% | +$12.8M |
|
|
KL
737
DELISTED
Kirkland Lake Gold Ltd Ordinary
KL
| $108M | 0.01% |
2,580,694
-9,242,203
| -78% | -$390M |
|
|
AEPPL
738
DELISTED
American Electric Power Company, Inc. Corporate Unit
AEPPL
| $108M | 0.01% |
2,158,816
-137,600
| -6% | -$6.78M |
|
|
SGI
739
Somnigroup International
SGI
$14B
| $108M | 0.01% |
2,293,470
-10,575
| -0.5% | -$479K |
|
740
BioMarin Pharmaceuticals
BMRN
$13.3B
| $108M | 0.01% |
1,219,033
+4,146
| +0.3% | +$342K |
|
741
Insulet
PODD
$10.1B
| $108M | 0.01% |
404,537
-6,474
| -2% | -$1.88M |
|
742
Medpace
MEDP
$16.3B
| $107M | 0.01% |
493,256
-19,973
| -4% | -$4.18M |
|
743
Onto Innovation
ONTO
$20.6B
| $107M | 0.01% |
1,056,235
+24,955
| +2% | +$2.15M |
|
744
Crocs
CROX
$6.32B
| $107M | 0.01% |
831,393
-26,606
| -3% | -$4.1M |
|
745
BJs Wholesale Club
BJ
$12B
| $107M | 0.01% |
1,590,299
+705,636
| +80% | +$44.1M |
|
|
FRC
746
DELISTED
First Republic Bank
FRC
| $106M | 0.01% |
514,537
-8,164
| -2% | -$1.72M |
|
747
Occidental Petroleum
OXY
$57.7B
| $106M | 0.01% |
3,665,087
-5,216
| -0.1% | -$164K |
|
748
Eaton
ETN
$176B
| $106M | 0.01% |
613,255
-20,776
| -3% | -$3.44M |
|
749
AGCO
AGCO
$6.97B
| $106M | 0.01% |
910,966
-54,908
| -6% | -$6.67M |
|
750
Illumina
ILMN
$29B
| $105M | 0.01% |
283,818
+6,375
| +2% | +$2.42M |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.